The full effects of GLP-1 medications on weight loss depend on factors such as dosage, metabolism, and overall health
[27] [28] Coadministration is expected to substantially increase the PDE5 inhibitor plasma concentrations and may result in increased associated adverse events including hypotension, syncope, visual changes, and prolonged erection
A significant share of patents comes from universities and research institutesespecially in South Korea, China, and the USindicating licensing potential for FMCG players
The mechanisms involved in the beneficial actions of GLP-1 receptor agonists on MASLD are indirect, given the virtual absence of GLP-1R in hepatocytes, except for those in T cells which are associated with anti-inflammatory effect.9 These include fat mass reduction, increased hepatic insulin sensitivity, reduced tissue lipotoxicity, anti-inflammatory effect and improved mitochondrial function32 (Fig